TRIAL RESULTS · SIDE EFFECTS
Teriparatide side effects
ANSWER
In 11 placebo-controlled trials with posted results, the most common side effects of Teriparatide were nasopharyngitis 14.1% (placebo 13.4%), hypercalciuria 11.3% (placebo 6.7%), back pain 9.5% (placebo 10.2%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
28
with an arm on Teriparatide, of 185 registered
Against placebo
11
placebo-controlled trials
People in those trials
1,735
on Teriparatide · 1,850 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Teriparatide beside placebo
Share of people with each side effect in 11 placebo-controlled trials with posted results: 1,735 people on Teriparatide (all doses), 1,850 on placebo, same trials. Listed only when reported for at least half of the people on Teriparatide. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
The 100 most reported of 1098 side effects reported
Every trial with posted results and an arm on Teriparatide (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Teriparatide | Placebo | Trials |
|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | 11.2% (306 of 2,729) | 13.4% | 17 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 3.9% (296 of 7,543) | 9.2% | 20 |
| Back pain | Musculoskeletal and connective tissue disorders | 3.8% (285 of 7,464) | 10.2% | 18 |
| Headache | Nervous system disorders | 2.9% (194 of 6,629) | 6.5% | 18 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 5.3% (157 of 2,965) | 5.2% | 16 |
| Dizziness | Nervous system disorders | 2.4% (150 of 6,346) | 5.2% | 16 |
| Fall | Injury, poisoning and procedural complications | 2.2% (147 of 6,541) | 5.1% | 14 |
| Nausea | Gastrointestinal disorders | 1.9% (133 of 6,963) | 3.8% | 19 |
| Urinary tract infection | Infections and infestations | 1.8% (125 of 6,776) | 4.3% | 14 |
| Hypercalciuria | Renal and urinary disorders | 10.2% (121 of 1,181) | 6.7% | 5 |
| Upper respiratory tract infection | Infections and infestations | 6.2% (113 of 1,813) | 5.6% | 9 |
| Influenza | Infections and infestations | 1.8% (109 of 6,204) | 6.2% | 13 |
| Constipation | Gastrointestinal disorders | 1.6% (102 of 6,536) | 4.5% | 15 |
| Hypertension | Vascular disorders | 1.4% (95 of 6,937) | 5.4% | 14 |
| Muscle spasms | Musculoskeletal and connective tissue disorders | 6.0% (82 of 1,365) | 2.3% | 10 |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | 1.0% (74 of 7,357) | 2.9% | 15 |
| Diarrhoea | Gastrointestinal disorders | 1.1% (64 of 5,907) | 4.9% | 15 |
| Bronchitis | Infections and infestations | 0.9% (60 of 6,529) | 1.5% | 15 |
| Contusion | Injury, poisoning and procedural complications | 2.0% (59 of 2,934) | 2.4% | 12 |
| Pneumonia | Infections and infestations | 0.7% (52 of 7,240) | 1.1% | 12 |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | 3.5% (43 of 1,246) | 2.8% | 8 |
| Insomnia | Psychiatric disorders | 3.2% (33 of 1,022) | 1.6% | 8 |
| Hypercalcaemia | Metabolism and nutrition disorders | 0.6% (33 of 5,651) | 0.1% | 8 |
| Hip fracture | Injury, poisoning and procedural complications | 0.5% (30 of 5,465) | - | 5 |
| Seasonal allergy | Immune system disorders | 6.8% (30 of 443) | 7.5% | 2 |
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | 5.4% (28 of 517) | 2.9% | 2 |
| Vomiting | Gastrointestinal disorders | 0.4% (27 of 6,085) | 0.6% | 10 |
| Fatigue | General disorders | 9.3% (27 of 290) | 4.3% | 5 |
| Cystitis | Infections and infestations | 3.6% (26 of 722) | 4.4% | 4 |
| Pyrexia | General disorders | 0.4% (24 of 5,451) | 0.6% | 7 |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.3% (23 of 6,700) | 0.1% | 8 |
| Myalgia | Musculoskeletal and connective tissue disorders | 4.1% (23 of 565) | 4.4% | 5 |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | 0.4% (22 of 5,580) | 0.0% | 8 |
| Gastritis | Gastrointestinal disorders | 0.4% (21 of 5,738) | 0.9% | 7 |
| Myocardial infarction | Cardiac disorders | 0.4% (21 of 5,000) | 0.4% | 5 |
| Gastroenteritis | Infections and infestations | 0.3% (20 of 6,205) | 1.0% | 10 |
| Palpitations | Cardiac disorders | 0.4% (20 of 5,186) | 0.6% | 7 |
| Eczema | Skin and subcutaneous tissue disorders | 3.5% (20 of 568) | 3.3% | 3 |
| Influenza like illness | General disorders | 8.9% (20 of 225) | 3.5% | 3 |
| Dermatitis contact | Skin and subcutaneous tissue disorders | 3.3% (19 of 571) | 2.1% | 3 |
| Cerebrovascular accident | Nervous system disorders | 0.3% (18 of 6,457) | 0.2% | 8 |
| Chills | General disorders | 0.4% (18 of 4,256) | 2.9% | 3 |
| Atrial fibrillation | Cardiac disorders | 0.3% (17 of 6,259) | 0.0% | 7 |
| Death | General disorders | 0.3% (17 of 5,234) | - | 4 |
| Small intestinal obstruction | Gastrointestinal disorders | 0.3% (16 of 5,036) | 0.3% | 4 |
| Stomatitis | Gastrointestinal disorders | 3.1% (16 of 517) | 3.8% | 2 |
| Tooth extraction | Surgical and medical procedures | 3.5% (16 of 462) | 2.1% | 2 |
| Chest pain | General disorders | 0.3% (15 of 5,488) | 0.2% | 7 |
| Injection site reaction | General disorders | 3.2% (15 of 462) | 4.6% | 2 |
| Periarthritis | Musculoskeletal and connective tissue disorders | 3.7% (15 of 408) | 6.0% | 1 |
| Abdominal pain | Gastrointestinal disorders | 0.2% (14 of 6,773) | 0.6% | 11 |
| Femur fracture | Injury, poisoning and procedural complications | 0.2% (14 of 6,202) | 0.5% | 7 |
| Dehydration | Metabolism and nutrition disorders | 0.3% (14 of 5,323) | 0.3% | 6 |
| Blood alkaline phosphatase increased | Investigations | 2.7% (14 of 517) | 2.5% | 2 |
| Vertigo | Ear and labyrinth disorders | 0.2% (13 of 6,217) | 0.7% | 9 |
| Cholelithiasis | Hepatobiliary disorders | 0.2% (13 of 5,822) | 0.0% | 8 |
| Cellulitis | Infections and infestations | 0.2% (13 of 5,782) | 0.0% | 6 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 0.2% (13 of 5,746) | 0.2% | 5 |
| Dyspepsia | Gastrointestinal disorders | 2.8% (13 of 463) | 4.0% | 4 |
| Humerus fracture | Injury, poisoning and procedural complications | 0.2% (12 of 6,937) | 0.0% | 9 |
| Syncope | Nervous system disorders | 0.2% (12 of 6,225) | 0.3% | 9 |
| Transient ischaemic attack | Nervous system disorders | 0.2% (12 of 6,364) | 0.1% | 8 |
| Oedema peripheral | General disorders | 0.9% (12 of 1,388) | 1.9% | 6 |
| Hypercalcemia | Metabolism and nutrition disorders | 8.6% (12 of 139) | 3.8% | 3 |
| Dental care | Surgical and medical procedures | 2.9% (12 of 408) | 0.5% | 1 |
| Cardiac failure congestive | Cardiac disorders | 0.2% (11 of 6,106) | 0.1% | 6 |
| Depression | Psychiatric disorders | 0.2% (11 of 4,945) | 1.4% | 6 |
| Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | 27.5% (11 of 40) | - | 1 |
| Radius fracture | Injury, poisoning and procedural complications | 0.2% (10 of 6,531) | 0.3% | 9 |
| Cataract | Eye disorders | 0.4% (10 of 2,348) | 0.8% | 7 |
| Anaemia | Blood and lymphatic system disorders | 0.2% (10 of 5,645) | 0.0% | 6 |
| Asthma | Respiratory, thoracic and mediastinal disorders | 0.2% (10 of 5,615) | 1.5% | 6 |
| Viral infection | Infections and infestations | 0.2% (10 of 5,294) | 0.3% | 5 |
| Sinusitis | Infections and infestations | 0.2% (10 of 4,310) | 2.4% | 4 |
| Diverticulitis | Infections and infestations | 0.2% (9 of 5,585) | 0.2% | 8 |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | 0.2% (9 of 4,546) | 2.1% | 6 |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | 0.2% (9 of 5,522) | 0.1% | 5 |
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | 0.2% (9 of 4,547) | 2.3% | 3 |
| Bone pain | Musculoskeletal and connective tissue disorders | 3.3% (9 of 276) | 2.9% | 3 |
| Procedural pain | Injury, poisoning and procedural complications | 6.8% (9 of 133) | 2.5% | 3 |
| Bleeding, bruising or irritation at injection site | Skin and subcutaneous tissue disorders | 22.5% (9 of 40) | - | 1 |
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | 45.0% (9 of 20) | 35.0% | 1 |
| Sciatica | Nervous system disorders | 0.4% (8 of 2,225) | 0.6% | 7 |
| Haematoma | Vascular disorders | 0.2% (8 of 4,388) | 0.2% | 6 |
| Rash | Skin and subcutaneous tissue disorders | 2.0% (8 of 392) | 0.7% | 6 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 0.1% (8 of 5,374) | 0.0% | 5 |
| Deep vein thrombosis | Vascular disorders | 0.2% (8 of 5,215) | 0.6% | 5 |
| Paraesthesia | Nervous system disorders | 0.2% (8 of 4,524) | 0.7% | 5 |
| Nausea/Vomitting | Gastrointestinal disorders | 20.0% (8 of 40) | - | 1 |
| HYPOCALCEMIA | Metabolism and nutrition disorders | 40.0% (8 of 20) | 5.0% | 1 |
| Cough | Respiratory, thoracic and mediastinal disorders | 2.0% (7 of 351) | 3.9% | 7 |
| Appendicitis | Infections and infestations | 0.1% (7 of 5,928) | 0.0% | 7 |
| Ankle fracture | Injury, poisoning and procedural complications | 0.1% (7 of 6,128) | 0.1% | 6 |
| Acute myocardial infarction | Cardiac disorders | 0.1% (7 of 5,818) | 0.0% | 6 |
| Upper limb fracture | Injury, poisoning and procedural complications | 0.1% (7 of 5,987) | 0.2% | 5 |
| Wrist fracture | Injury, poisoning and procedural complications | 0.1% (7 of 5,978) | 0.0% | 5 |
| Intestinal obstruction | Gastrointestinal disorders | 0.1% (7 of 6,048) | 0.1% | 5 |
| Cholecystitis acute | Hepatobiliary disorders | 0.1% (7 of 5,946) | 0.1% | 4 |
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | 0.1% (7 of 5,265) | 0.7% | 4 |
| Pharyngitis | Infections and infestations | 2.2% (7 of 318) | 0.0% | 3 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
FDA LABEL
What the FDA label says
Forteo NDA021318 · label of 2026-08-03 Regulator
Most common adverse reactions (>10%) include: arthralgia, pain, and nausea.
Teriparatide ANDA213641 · label of 2026-03-12 Regulator
Most common adverse reactions (>10%) include: arthralgia, pain, and nausea.
Bonsity NDA211939 · label of 2025-06-01 Regulator
Most common adverse reactions (>10%) include: arthralgia, pain, and nausea.
QUESTIONS
Does teriparatide cause nasopharyngitis?
In 11 placebo-controlled trials with posted results, 14.1% of people on teriparatide reported nasopharyngitis, against 13.4% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does teriparatide cause hypercalciuria?
In 11 placebo-controlled trials with posted results, 11.3% of people on teriparatide reported hypercalciuria, against 6.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does teriparatide cause back pain?
In 11 placebo-controlled trials with posted results, 9.5% of people on teriparatide reported back pain, against 10.2% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does teriparatide cause arthralgia?
In 11 placebo-controlled trials with posted results, 9.1% of people on teriparatide reported arthralgia, against 9.2% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does teriparatide cause headache?
In 11 placebo-controlled trials with posted results, 7.6% of people on teriparatide reported headache, against 6.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
185 registered clinical trials of Teriparatide
The 10 most recently updated are listed.
| NCT03994172 | Novel Combination Therapy for Osteoporosis in Men Status: COMPLETED · Updated 2026-09-03 |
|---|---|
| NCT07242612 | Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis Status: COMPLETED · Updated 2026-08-13 |
| NCT06164795 | Sequential Therapies After Osteoanabolic Treatment Status: RECRUITING · Updated 2026-07-22 |
| NCT07497503 | A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants Status: RECRUITING · Updated 2026-07-16 |
| NCT03735537 | Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid Status: COMPLETED · Updated 2026-06-11 |
| NCT01293292 | Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action Status: COMPLETED · Updated 2026-05-19 |
| NCT03770338 | Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery Status: ACTIVE_NOT_RECRUITING · Updated 2026-05-14 |
| NCT05151484 | Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover Status: ACTIVE_NOT_RECRUITING · Updated 2026-05-14 |
| NCT07579936 | A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens Status: RECRUITING · Updated 2026-05-12 |
| NCT01155232 | Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis Status: ACTIVE_NOT_RECRUITING · Updated 2026-05-11 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.